These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38480110)

  • 1. Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. 2024;85:125-38.
    Fodor A; Brombin C; Chiti A; Di Muzio N
    Eur Urol; 2024 Oct; 86(4):e93-e94. PubMed ID: 38480110
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Pawel Rajwa, Takafumi Yanagisawa, Manuel Gruber, et al. Surgical Metastasectomy for Visceral and Bone Prostate Cancer Metastases: A Mini-review. Eur Urol Focus 2023;9:232-5.
    Bravi CA; Mottrie A; Briganti A; Montorsi F
    Eur Urol Focus; 2023 May; 9(3):549. PubMed ID: 36528510
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007.
    Gandaglia G; Briganti A; Raggi D; Marandino L; Necchi A; Di Maio M; Montorsi F
    Eur Urol Focus; 2024 May; 10(3):497. PubMed ID: 36813620
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Pawel Rajwa, Daniele Robesti, Michael Chaloupka, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.006.
    Onal C; Elmali A; Cem Guler O
    Eur Urol Oncol; 2024 Jun; 7(3):644-645. PubMed ID: 38365504
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2022;82:82-96.
    Murthy V; Chilukuri S; Maitre P
    Eur Urol; 2022 Oct; 82(4):e105-e106. PubMed ID: 35907662
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
    Goonewardene SS; Persad R; Young A; Makar A
    Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Giorgio Gandaglia, Alberto Briganti, Daniele Raggi, et al's Letter to the Editor re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007.
    Hoeh B; Chun FKH; Mandel P
    Eur Urol Focus; 2024 May; 10(3):498. PubMed ID: 36813619
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82.
    Liu W; Zukotynski K; Bauman G
    Eur Urol; 2021 Sep; 80(3):e77-e78. PubMed ID: 34130872
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
    Parker C; Sydes MR; Kynaston H;
    Eur Urol; 2013 Nov; 64(5):e102. PubMed ID: 23953599
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Friedrich O Hartung, Karl-Friedrich Kowalewski, Jost von Hardenberg, et al. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus 2022;8:545-54.
    Montorsi F; Capogrosso P; Zaffuto E; Dehò F
    Eur Urol Focus; 2024 May; 10(3):489. PubMed ID: 36774272
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.
    Drewa T; Chlosta P
    Eur Urol; 2010 Feb; 57(2):e18-9; author reply e20. PubMed ID: 19853990
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
    Fanti S; Krause B; Weber W; Castellucci P; Grosu AL; de Jong IJ; Messa C; Picchio M; Pruim J; Langsteger W; Chiti A;
    Eur Urol; 2011 Nov; 60(5):e37-8; author reply e39-41. PubMed ID: 21855205
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Ofer Yossepowitch, Anders Bjartell, James A. Eastham, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87-99.
    Kynaston H; Parker CC; Sydes MR;
    Eur Urol; 2009 Jun; 55(6):e107. PubMed ID: 19303202
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N; Singh PB; Martin FL; Baird AD
    Eur Urol; 2009 Feb; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: M. Minhaj Siddiqui, Soroush Rais-Bahrami, Hong Truong, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 2013;64:713-9 and Re: Mark Emberton. Has magnetic resonance-guided biopsy of the prostate become the standard of care? Eur Urol 2013;64:720-1.
    van den Bergh RC; van der Poel HG
    Eur Urol; 2014 Jun; 65(6):e106-7. PubMed ID: 24411989
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30: Radical Prostatectomy Versus Radiation for Clinically Localized Prostate Cancer: Two Systematic Reviews and a Randomized Controlled Trial.
    Lazar AA; Lizarraga TLC; Roach M
    Eur Urol; 2016 Jul; 70(1):e13-e14. PubMed ID: 26935558
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82.
    Glicksman RM; Berlin A
    Eur Urol; 2021 Sep; 80(3):e79-e80. PubMed ID: 34158186
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
    Kirollos MM
    Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Axel Heidenreich, Gunnar Aus, Michel Bolla, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
    Kirollos M
    Eur Urol; 2008 Sep; 54(3):693-5; author reply 695-7. PubMed ID: 18367315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.